How effective is levoketoconazole?

The approval of levoketoconazole has a solid clinical research basis and is mainly used to treat endogenous hypercortisolemia in adult patients with Cushing's syndrome who cannot choose surgery or have not yet been cured by surgery. Levoketoconazole is an important, welcome new treatment option for clinicians to help manage patients with endogenous Cushing's syndrome, a serious, potentially life-threatening rare disease that can cause multisystem signs and symptoms if not treated appropriately.

Two positivePhase 3 studies evaluated 166 adult patients with Cushing's syndrome in the United States. The SONICS study significantly reduced and normalized the mean urinary free cortisol concentration without increasing the dose, while the LOGICS study confirmed its effectiveness and safety in normalizing and maintaining treatment response. The SONICS study met its primary and key secondary endpoints, significantly reducing and normalizing mean urinary free cortisol concentrations without increasing dose.

From the mechanism of action, levoketoconazole targets the key enzyme in cortisol biosynthesis-11β-hydroxylase. By inhibiting this enzyme, it reduces cortisol production and effectively solves the hypercortisolism characteristic of Cushing's syndrome. Compared with the racemic precursor ketoconazole, its unique stereochemical structure enhances the binding affinity to 11β-hydroxylase, provides a more targeted treatment method, reduces off-target effects, and has better safety.

It is of great significance in the field of treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome, especially in patients who are inoperable or have not been cured by surgery. Cushing's syndrome is a serious and potentially life-threatening rare disease. Improper treatment can cause multi-system problems, and levoketoconazole provides a new way for clinical treatment.

Reference materials:https://go.drugbank.com/drugs/DB05667